1. This study conducted a routine surveillance of SARS-CoV-2 genomes in Beijing over the last 3 years, and found that there were no persistently dominant variants or novel lineages.
2. Two variants, BA.5.2 and BF.7, are currently dominant in Beijing, accounting for 90% of local cases since Nov 14 (315 of 350 local cases sequenced in this study).
3. The effective population size for both BA.5.2 and BF.7 in Beijing increased after Nov 14, 2022
The article is generally reliable and trustworthy as it provides detailed information on the epidemiology and phylogeny of high-quality complete genome sequences of SARS-CoV-2 collected in 2022 in Beijing, China. The authors have provided evidence to support their claims by conducting next-generation sequencing to generate the SARS-CoV-2 genomes and performing phylogenetic and population dynamic analyses using high-quality complete sequences. Furthermore, they have also discussed potential risks associated with the emergence of novel SARS-CoV-2 variants and highlighted the importance of long-term monitoring of SARS-CoV-2 at the genomic level for global response to COVID-19 pandemic.
However, there are some points that could be improved upon such as providing more details on the methodology used for collecting respiratory samples from imported and local cases in Beijing over the last 3 years; providing more information on how they randomly selected samples for analysis; providing more details on how they performed phylogenetic and population dynamic analyses; discussing potential biases associated with their findings; exploring counterarguments to their findings; presenting both sides equally; noting possible risks associated with their findings; etc.